Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis
Allergy · 2025
DOI: 10.1111/all.16618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Florence Schleich und 14 weiteren Autor:innen. Beteiligte Einrichtung: GIGA I3, Respiratory Medicine, Exercise Physiology Laboratory, University of Liège, Liège, Belgium. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Nasal Polyps, Sinusitis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK-sponsored study 219821.
Abstract (Originalsprache)
Background
Severe asthma with an eosinophilic phenotype (SAEP) and chronic rhinosinusitis with nasal polyps (CRSwNP) are predominantly type 2‐driven diseases, characterised by eosinophilic inflammation and substantial disease burden. Mepolizumab, a humanised monoclonal antibody that targets interleukin‐5, a key cytokine in type 2 inflammation, is an effective, approved treatment both in SAEP and CRSwNP. We aimed to analyse real‐world evidence of mepolizumab effectiveness in patients with comorbid SAEP and CRSwNP.
Methods
This study pooled five existing, predominantly European cohorts to describe the impact of mepolizumab on the rate of clinically significant exacerbations (CSEs) and other outcomes in adults with SAEP without and with comorbid CRSwNP (SAEP[−]CRSwNP and SAEP[+]CRSwNP, respectively).
Results
Overall, 1037 patients were included. Baseline characteristics were similar in both cohorts. Mepolizumab was associated with a reduction from baseline in the annual rate of CSEs at 12‐months post‐initiation (SAEP[−]CRSwNP: 72.7%; SAEP[+]CRSwNP: 79.7%), irrespective of baseline blood eosinophil count (BEC). When patients with SAEP[+]CRSwNP were compared with patients with SAEP[−]CRSwNP, a 30.0% incremental benefit in the reduction of CSEs was observed. At 12‐months post‐initiation, mepolizumab was also associated with a reduction in oral corticosteroid use and BEC, and an improvement in lung function and Asthma Control Test (ACT) scores in both cohorts. Post‐mepolizumab initiation, ≥ 3 clinical remission criteria were fulfilled by 47.2% and 52.3% of patients with SAEP[−]CRSwNP and SAEP[+]CRSwNP, respectively.
Conclusions
The results provide a greater understanding of mepolizumab's effectiveness, demonstrating a substantial improvement in asthma outcomes, irrespective of baseline BEC and the presence of comorbid CRSwNP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GIGA I3, Respiratory Medicine, Exercise Physiology Laboratory, University of Liège, Liège, Belgium.
- 2nd Respiratory Medicine Department Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- University of Glasgow, Glasgow, Scotland, UK.
- Cantonal Hospital Baselland, Liestal and Medical Faculty, University of Basel, Basel, Switzerland.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
ORCID-Profile: Stelios Loukides, Ines Palomares
Förderung
- GSK-sponsored study 219821
Zitieren
APA
Schleich, F., Loukides, S., Chaudhuri, R., Leuppi, J. D., Heffler, E., Domingo, C., Micheletto, C., Paulsson, T., Gaw, N., Kallinikou, K., Vossen, C., Guelfucci, F., Menon, J., Ngami, A., & Palomares, I. (2025). Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis. Allergy. https://doi.org/10.1111/all.16618
Vancouver
Schleich F, Loukides S, Chaudhuri R, Leuppi JD, Heffler E, Domingo C, et al. Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis. Allergy. 2025. doi:10.1111/all.16618
BibTeX
@article{Schleich2025,
author = {Schleich, Florence and Loukides, Stelios and Chaudhuri, Rekha and Leuppi, Joerg D and Heffler, Enrico and Domingo, Cristian and Micheletto, Claudio and Paulsson, Thomas and Gaw, Nina and Kallinikou, Konstantina and Vossen, Carla and Guelfucci, Florent and Menon, Jyothi and Ngami, Armel and Palomares, Ines},
title = {Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16618}
}
EUVIMED